Brenton Saunders
Chief Executive Officer @ Bausch & Lomb
Parsippany, United States
Brenton Saunders is a seed investor at Bausch & Lomb in Parsippany focused on Health Care and Medical. Brenton Saunders is the current Chief Executive Officer of Bausch & Lomb. He previously worked at The Allergan Foundation as a Chairman. Brenton Saunders attended Temple University’s Fox School of Business.
- Total investments:
- 9
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Brenton Saunders invests in
Stages Brenton Saunders invests in
Countries Brenton Saunders invests in
Round sizes
Round size
- Seed
- $3.5M–$14M
- Series A
- $20M–$23M
- Series B
- $40M–$60M
Investment Focus
Industry
- Health Care 5 (56%)
- Medical 3 (33%)
- Biotechnology 3 (33%)
- Wellness 2 (22%)
- Biopharma 2 (22%)
Stage
- Seed 3 (33%)
- Series A 2 (22%)
- Series B 2 (22%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Lipidio Pharmaceuticals
|
Lipidio Pharmaceuticals is a healthcare company that focuses on advancing a molecule to treat diseases associated with excess body fat. It includes non-alcoholic steatohepatitis, Prader-Willi syndrome, and antipsychotic drug-induced weight gain. The company was founded in 2018 and headquartered in San Diego, California. | $20M / Series A / Nov 10, 2022 | |
Wondermind
|
Wondermind operates as a mental fitness ecosystem with a mission to democratize and destigmatize mental health globally via daily content, CPG products, and storytelling. | $5M / Seed / Aug 11, 2022 | |
Nucleus
|
Nucleus provides genetic analysis of greater breadth, depth, and beauty. Users can upload their genetic information obtained through an established company. The proprietary algorithms will calculate polygenic risk scores and measure disease risk based on analysis of genetic variants and display them in a user-friendly platform. | $14M / Seed / Jul 14, 2022 | |
Inflection Points
|
Inflection Points provides training in bitcoin and crypto. | $12.6M / Seed / Jul 13, 2022 | |
Osmind
|
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-based medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org. | $40M / Series B / May 10, 2022 | |
NUE Life Health
|
NUE Life aims to improve mental wellness by enhancing brain function, performance, and longevity through evidence-based and scientifically proven mental health treatments and products. NUE Life has created a therapeutic ecosystem of ketamine therapy, an interactive companion app, and virtual aftercare programs to help people heal. | $23M / Series A / Apr 19, 2022 | |
|
Nucleus
|
Nucleus provides genetic analysis of greater breadth, depth, and beauty. Users can upload their genetic information obtained through an established company. The proprietary algorithms will calculate polygenic risk scores and measure disease risk based on analysis of genetic variants and display them in a user-friendly platform. | $3.5M / Seed / Dec 15, 2021 | |
|
Nucleus
|
Nucleus provides genetic analysis of greater breadth, depth, and beauty. Users can upload their genetic information obtained through an established company. The proprietary algorithms will calculate polygenic risk scores and measure disease risk based on analysis of genetic variants and display them in a user-friendly platform. | $3.5M / Seed / Dec 15, 2021 | |
Cambrian Biopharma
|
Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is todevelop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age. | $60M / Series B / Feb 09, 2021 |
Co-Investors
About Bausch & Lomb
Bausch + Lomb is the eye health company dedicated to Bringing Visionary Ideas to Eye Health.They offer the world’s most comprehensive portfolio of eye health products, and They have one of the oldest, best known and most respected healthcare brands in the world.The company began in 1853 in Rochester, New York, as a small optical shop thatgrew to become a multi-billion dollar corporation with approximately 13,000 employees worldwide, and with products available in more than 100 countries.
Bausch & Lomb Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Brenton Saunders
Chief Executive Officer
|
|||
Robert Bertolini
President & CFO
|
|||
Bob Palmisano
Executive
|
|||
Chad Speegle
Territory Manager
|
|||
Joseph Landy
Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Brenton Saunders invest in?
Brenton Saunders invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Series A stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Brenton Saunders's check size?
Brenton Saunders typically joins rounds of $3.5M–$14M at Seed, $20M–$23M at Series A and $40M–$60M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Brenton Saunders participates in.
When did Brenton Saunders last invest?
The most recent investment recorded for Brenton Saunders closed in Nov 2022. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
